专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2004012680A2 LIPID-DRUG COMPLEXES IN REVERSED LIQUID AND LIQUID CRYSTALLINE PHASES 审中-公开
标题翻译：反相液相和液晶相中的脂质 - 药物复合物
公开(公告)号：WO2004012680A2
公开(公告)日：2004-02-12
申请号：PCT/US2003/024512
申请日：2003-08-06
申请人： LYOTROPIC THERAPEUTICS, INC.
发明人： ANDERSON, David, M.
IPC分类号： A61K
CPC分类号： A61K9/1274 , A61K47/541 , A61K47/55
摘要： A pharmaceutical is formulated to enable enhanced delivery across membrane barriers, permit solubilization, protect compounds from deactivation by thiol containing compounds in the body, and allow retention of the drug during transport to a desired site of activity. The pharmaceutical includes a complex of two moieties where at least one is pharmaceutically active and is larger than a single atom in size, and the second moiety, when combined with a cationic or anionic counterion forms either a pharmaceutically acceptable anionic or cationic surfactant or a pharmaceutically acceptable salt that has an octanol water partition coefficient of greater than about 100.
摘要翻译：配制药物以增强穿过膜屏障的递送，允许溶解，保护化合物免受体内含硫醇化合物的失活，并允许药物在运输至期望的活性部位期间保留。药物包括两个部分的复合物，其中至少一个具有药学活性并且大于单个原子的大小，并且当第二部分与阳离子或阴离子平衡离子结合时形成药学上可接受的阴离子或阳离子表面活性剂或药学上可接受的辛醇水分配系数大于约100的可接受盐。

2. 发明申请

WO2003106589A1 A NANOPOROUS PARTICLE WITH A RETAINED TARGET 审中-公开
标题翻译：具有保留目标的纳米颗粒
公开(公告)号：WO2003106589A1
公开(公告)日：2003-12-24
申请号：PCT/US2002/018657
申请日：2002-06-13
申请人： LYOTROPIC THERAPEUTICS, INC.
发明人： ANDERSON, David, M.
IPC分类号： C09K19/00
CPC分类号： B82Y5/00 , C09K19/00 , C12Q1/68 , G01N33/5436 , C12Q2565/629
摘要： Porous nanostructured materials, such as porous nanostructured liquid and liquid crystalline particles or materials, incorporate a target substantially within the material which selectively binds a chemical of interest which can diffusion within the porous nanostructured material and be bound by the target. The porous nanostructured materials can be dispersed as particles in a medium in which said chemical of interest is located with low turbidity. Markers which detect binding of said chemical of interest can be maintained in the medium separate and apart from the target, and any active compound (e.g., an enzyme) associated therewith by the porous nanostructured material, such that detectable changes in the maker only result when the active compounds diffuse out of the porous nanostructured materials after the chemical of interest binds to the target.
摘要翻译：多孔纳米结构材料，例如多孔纳米结构化液体和液晶颗粒或材料，将基本上在目标物质内的目标物结合的材料中，靶材料选择性地结合目的化学物质，其可在多孔纳米结构化材料内扩散。多孔纳米结构材料可以作为颗粒分散在所述感兴趣的化学物质位于低浊度的介质中。检测所述化学物质的结合的标记物可以在分离和分离靶的培养基以及与多孔纳米结构材料相关联的任何活性化合物（例如，酶）中保持，使得制造商的可检测变化仅在感兴趣的化学物质结合靶之后，活性化合物从多孔纳米结构材料中扩散出来。

3. 发明申请

WO2005034872A2 DRUG-DELIVERY VEHICLES BASED ON REVERSED LIQUID CRYSTALLINE PHASE MATERIALS 审中-公开
标题翻译：基于反相液相材料的药物递送车辆
公开(公告)号：WO2005034872A2
公开(公告)日：2005-04-21
申请号：PCT/US2004/033193
申请日：2004-10-08
申请人： LYOTROPIC THERAPEUTICS, INC.
发明人： ANDERSON, David, M. , CAMERANSI, Benjamin, G. Jr.
IPC分类号： A61K
CPC分类号： C09K19/02 , A61K9/1274
摘要： Uncoated particles of reversed cubic phase or reversed hexagonal phase material containing an active disposed within are provided. The uncoated particles have an ionic charge that is sufficient to stabilize them in dispersion in a liquid, e.g. a polar solvent. The active that is disposed within the particles may be, for example, a pharmaceutical or nutriceutical compound. The invention also contemplates drug formulations containing reversed hexagonal and reversed cubic phases that can be applied to significantly increase the duration of action of the drug and/or provide the same duration and efficiency at a significantly lower dose.
摘要翻译：提供了包含设置在其内的活性物质的反相立方相或反六方相材料的未涂覆颗粒。未涂覆的颗粒具有足以使其稳定在液体分散中的离子电荷，例如，极性溶剂。设置在颗粒内的活性物质可以是例如药物或营养化合物。本发明还考虑了含有反向六方晶和反相立方相的药物制剂，其可用于显着增加药物作用的持续时间和/或以显着较低的剂量提供相同的持续时间和效力。

4. 发明申请

WO2003106168A1 COATED PARTICLES, METHODS OF MAKING AND USING 审中-公开
标题翻译：包衣颗粒，制造和使用方法
公开(公告)号：WO2003106168A1
公开(公告)日：2003-12-24
申请号：PCT/US2002/018654
申请日：2002-06-13
申请人： LYOTROPIC THERAPEUTICS, INC.
发明人： ANDERSON, David, M.
IPC分类号： B32B15/04
CPC分类号： A01N25/26 , A61K9/1274 , B01J13/02 , B82Y5/00 , Y10T428/2984 , Y10T428/2985 , Y10T428/2989
摘要： A particle coated with a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material includes an internal matrix core having at least one a nanostructured liquid phase, or at least one nanostructured liquid crystalline phase or a combination of the two is used for the delivery of active agents such as pharmaceuticals, nutrients, pesticides, etc. The coated particle can be fabricated by a variety of different techniques where the exterior coating is a nonlamellar material such as a nonlamellar crystalline material, a nonlamellar amorphous material, or a nonlamellar semi-crystalline material.
摘要翻译：涂覆有非纤维材料如非晶体结晶材料，非平板非晶材料或非平板半结晶材料的颗粒包括具有至少一个纳米结构液相或至少一个纳米结构液晶相或两者的组合用于递送活性剂如药物，营养物，农药等。涂覆的颗粒可以通过各种不同的技术制造，其中外部涂层是非水性材料，例如非平板结晶材料，非层状无定形材料或非平板半结晶材料。

5. 发明申请

WO2003000236A1 PARTICLES WITH IMPROVED SOLUBILIZATION CAPACITY 审中-公开
标题翻译：具有改善溶解能力的颗粒
公开(公告)号：WO2003000236A1
公开(公告)日：2003-01-03
申请号：PCT/US2002/019623
申请日：2002-06-21
申请人： LYOTROPIC THERAPEUTICS, INC
发明人： ANDERSON, David, M.
IPC分类号： A61K9/14
CPC分类号： A61K9/1274 , A61K9/1075 , A61K36/00 , Y10T428/2989 , Y10T428/31544 , A61K2300/00
摘要： A particle is disclosed that comprises a first volume of hydrophobe-rich material with tunable dissolution and solubilization characteristics and a distinct second volume of nanostructural nonlamellar liquid crystalline material, said second volume containing said first domain and being capable of being in equilibrium with said first volume. Preferably, the nanostructured nonlamellar liquid crystalline material is capable of being in equilibrium with a polar solvent or a water-immiscible solvent or both.
摘要翻译：公开了一种颗粒，其包含具有可调溶解和溶解特性的第一体积的富含疏水物的材料和不同的第二体积的纳米结构非水性液晶材料，所述第二体积包含所述第一结构域并且能够与所述第一体积平衡。优选地，纳米结构非水性液晶材料能够与极性溶剂或与水不混溶的溶剂或两者均衡。

6. 发明申请

WO2010148288A2 PHARMACEUTICAL FORMULATIONS WITH LOW AQUEOUS LEVELS OF FREE UNBOUND DRUG 审中-公开
标题翻译：具有低水平水平的药物制剂
公开(公告)号：WO2010148288A2
公开(公告)日：2010-12-23
申请号：PCT/US2010/039139
申请日：2010-06-18
申请人： LYOTROPIC THERAPEUTICS, INC. , ANDERSON, David, M.
发明人： ANDERSON, David, M.
IPC分类号： A61K47/40 , A61K9/16 , A61K9/20 , A61K31/05
CPC分类号： A61K31/05 , A61K9/1664 , A61K47/26
摘要： The complexation properties of cyclodextrins are combined with the partitioning properties of reversed lyotropic liquid crystalline phase microparticles to prepare pharmaceutical formulation dispersions with reduced levels of free unbound aqueous drug. Safe to inject formulations including, for example, propofol, include dispersions of reversed lyotropic liquid crystalline phase microparticles with propofol in an aqueous carrier together with cyclodextrins.
摘要翻译：将环糊精的络合性质与反相溶致液晶微粒的分配性质结合，制备具有降低水平的游离未结合水性药物的药物制剂分散体。包括例如异丙酚在内的配制剂的安全性包括与水解载体中的反相溶致液晶微粒与异丙酚的分散体与环糊精。

7. 发明申请

WO2003000057A1 SOLVENT SYSTEM 审中-公开
标题翻译：溶剂系统
公开(公告)号：WO2003000057A1
公开(公告)日：2003-01-03
申请号：PCT/US2002/018646
申请日：2002-06-13
申请人： LYOTROPIC THERAPEUTICS, INC.
发明人： ANDERSON, David, M.
IPC分类号： A01N43/42
CPC分类号： A61K47/18 , A61K9/0019 , A61K9/1274 , A61K47/10
摘要： A solvent system for the solution in a polar solvent of a poorly soluble compound having pharmacological activity is disclosed that comprises a first polar organic material comprising a sugar having at least two hydroxyl groups or an alcohol of two or three carbons having at least two hydroxyl groups or both and a second polar organic material comprising an amide group or an ammonium group or both., such as one or more of acetamide, ethylammonium nitrate, N-methylacetamide and dimethylacetamide, preferably an amide.
摘要翻译：公开了具有药理活性的难溶性化合物的极性溶剂中的溶液的溶剂体系，其包含含有至少两个羟基的糖的第一极性有机材料或具有至少两个羟基的两个或三个碳的醇或两者，以及包含酰胺基或铵基或二者的第二极性有机材料，例如乙酰胺，硝酸乙铵，N-甲基乙酰胺和二甲基乙酰胺中的一种或多种，优选酰胺。

8. 发明申请

WO2006063174A3 COMPOSITIONS FOR BINDING TO ASSAY SUBSTRATA AND METHODS OF USING 审中-公开
公开(公告)号：WO2006063174A3
公开(公告)日：2006-06-15
申请号：PCT/US2005/044495
申请日：2005-12-08
申请人： LYOTROPIC THERAPEUTICS, INC.
发明人： ANDERSON, David, M. , SAUL, Richard, G.
IPC分类号： G01N21/00 , G01N33/53 , G01N33/543
摘要： Compositions and methods for binding to assay substrata in a stable and protective manner, thereby enhancing assay performance, are provided. The compositions comprise lyotropic materials (for example, lyotropic liquid and/or liquid crystalline materials) and may contain macromolecular standards, markers or capture compounds. The compositions are capable of binding to assay substrata such as that of chips that are employed for MALDI and SELDI mass spectroscopy analyses and plates that are used for ELISA type assays.

9. 发明申请

WO2003106382A3 REVERSED LIQUID CRYSTALLINE PHASES WITH NON-PARAFFIN HYDROPHOBES 审中-公开
公开(公告)号：WO2003106382A3
公开(公告)日：2003-12-24
申请号：PCT/US2003/018457
申请日：2003-06-13
申请人： LYOTROPIC THERAPEUTICS, INC.
发明人： ANDERSON, David, M.
IPC分类号： A61K9/00
摘要： Compounds which are otherwise difficult to solubilize, such as, for example, pharmaceutical actives difficult for the body to absorb, are solubilized into a composition using a solvent system that is a structured fluid. The structured fluid is a reversed cubic phase or reversed hexagonal phase material, or a combination thereof, which includes a polar solvent, a surfactant and a non-paraffinic liquid with a high octanol-water partition coefficient which does not qualify as a surfactant. The compositions thus formed are able to enhance absorption of drugs by the induction of local, transient nanopores in biomembrane absorption barriers and particularly those in which efflux mechanisms, such as those associated with P-glycoprotein and/or cytochrome 3A4, are active. The compositions and methods that are used for solubilizing pharmaceutical actives in structured fluids can simultaneously accomplish solubilization of difficultly soluble drugs and enhancement of absorption.

10. 发明申请

WO2003106382A2 REVERSED LIQUID CRYSTALLINE PHASES WITH NON-PARAFFIN HYDROPHOBES 审中-公开
标题翻译：具有非对映体疏水性的反相液晶相
公开(公告)号：WO2003106382A2
公开(公告)日：2003-12-24
申请号：PCT/US2003/018457
申请日：2003-06-13
申请人： LYOTROPIC THERAPEUTICS, INC.
发明人： ANDERSON, David, M.
IPC分类号： C07C
CPC分类号： A61K9/1274
摘要： Compounds which are otherwise difficult to solubilize, such as, for example, pharmaceutical actives difficult for the body to absorb, are solubilized into a composition using a solvent system that is a structured fluid. The structured fluid is a reversed cubic phase or reversed hexagonal phase material, or a combination thereof, which includes a polar solvent, a surfactant and a non-paraffinic liquid with a high octanol-water partition coefficient which does not qualify as a surfactant. The compositions thus formed are able to enhance absorption of drugs by the induction of local, transient nanopores in biomembrane absorption barriers and particularly those in which efflux mechanisms, such as those associated with P-glycoprotein and/or cytochrome 3A4, are active. The compositions and methods that are used for solubilizing pharmaceutical actives in structured fluids can simultaneously accomplish solubilization of difficultly soluble drugs and enhancement of absorption.
摘要翻译：否则难以溶解的化合物，例如难以吸收身体的药物活性成分，可以使用作为结构化流体的溶剂体系溶解到组合物中。结构化流体是反相立方相或反相六方相材料或其组合，其包括极限溶剂，表面活性剂和具有高辛醇 - 水分配系数的非石蜡液体，其不被认为是表面活性剂。由此形成的组合物能够通过诱导生物膜吸收屏障中的局部，瞬时纳米孔而增强药物的吸收，特别是其中外源机制（例如与P-糖蛋白和/或细胞色素3A4相关的那些）是活性的那些。用于溶解结构化流体中的药物活性物质的组合物和方法可以同时完成难溶性药物的溶解和增强吸收。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式